Datapoint: Latest Patent Ruling Protects Imbruvica Until 2032

AbbVie and Johnson & Johnson last week won a patent lawsuit in favor of their oncology drug Imbruvica, which now won’t see generic competition until at least 2032. The legal battle against Alvogen and Natco Pharma began in 2019. Imbruvica, which launched in 2014, is approved to treat several cancers, including chronic lymphocytic leukemia, mantle cell lymphoma and non-Hodgkin lymphoma. Under the pharmacy benefit, Imbruvica holds covered or better status for 71% of all insured lives.

SOURCE: MMIT Analytics, as of 9/1/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 24

Datapoint: Keytruda Scores Major Kidney Cancer Nod

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 23

Datapoint: Zing Health Acquires Lasso Healthcare

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 22

Datapoint: Paramount Loses Ohio Medicaid Battle

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today